Table I.
Baseline and treatment characteristics of patients stratified according to the POSEIDON criteria.
| POSEIDON Groups |
||||||||
|---|---|---|---|---|---|---|---|---|
| Group 1 n = 1997 |
Group 2 n = 1568 |
Group 3 n = 245 | Group 4 n = 623 | Total n = 4433 | Group 5 (Non-POSEIDON) n = 4640 | |||
| 1a n = 212 | 1b n = 1785 | 2a n = 293 | 2b n = 1275 | |||||
| Baseline characteristics: | ||||||||
| Female Age (years) | 31 [28; 33] | 31 [28; 34] | 39 [37–41] | 38 [36; 40] | 32 [30; 33] | 39 [37; 42] | 34 [31; 38] | 31 [28; 35] |
| BMI (kg/m2) | 22 [20–25] | 22 [20–26] | 22 [20–25] | 22 [21; 25] | 21 [20; 23] | 22 [20; 24] | 22 [20; 25] | 22 [20; 25] |
| Infertility duration (months) | 48 [24–72] | 48 [24–72] | 48 [24–96] | 60 [24; 102] | 48 [24–72] | 60 [24; 108] | 48 [24–84] | 48 [24–72] |
|
Infertility cause, n (%): |
||||||||
| Male factor | 47 (29.4) | 515 (28.9) | 43 (10.2) | 281 (22.0) | 26 (10.6) | 77 (12.4) | 989 (22.3) | 1771 (38.1) |
| Tubal | 13 (5.7) | 176 (9.8) | 30 (6.8) | 143 (11.2) | 22 (9.0) | 42 (6.7) | 426 (9.6) | 523 (11.2) |
| Endometriosis | 13 (5.7) | 91 (5.1) | 17 (5.8) | 44 (3.4) | 14 (5.7) | 61 (9.8) | 240 (5.4) | 152 (3.3) |
| Ovulatory | 17 (8.0) | 104 (5.8) | 10 (3.4) | 35 (2.7) | 5 (2.0) | 7 (1.1) | 178 (4.0) | 649 (14.0) |
| Unexplained | 49 (23.1) | 492 (27.6) | 71 (24.2) | 287 (22.5) | 86 (35.1) | 182 (29.2) | 1167 (26.3) | 1089 (23.6) |
| Combined* | 73 (34.4) | 407 (22.8) | 122 (41.6) | 485 (38.2) | 92 (37.6) | 254 (40.8) | 1433 (32.4) | 456 (9.8) |
| AFC (n) | 7 [6–12] | 11 [8–16] | 6 [5–8] | 8 [6; 11] | 3 [2; 4] | 3 [2; 4] | 8 [5; 12] | 17 [13; 22] |
| AMH (ng/mL)ϒ | 1.2 [0.7–2.8] | 2.5 [1.4–4.5] | 1.1 [0.6–1.9] | 1.6 [1.1; 2.8] | 0.7 [0.3; 1.2] | 0.7 [0.3; 1.1] | 1.4 [0.8; 2.8] | 4.8 [2.9; 7.7] |
| Treatment characteristics: | ||||||||
| Stimulation duration (days) | 9 [8–10] | 9 [8–10] | 9 [8–10] | 9 [8–10] | 10 [8–11] | 9.5 [8–11] | 9 [8–10] | 9 [8–10] |
| GnRH analogue: | ||||||||
| Antagonist | 149 (70.3) | 1261 (70.6) | 238 (81.2) | 927 (72.7) | 207 (84.5) | 574 (92.1) | 3356 (75.7) | 3817 (82.3) |
| Agonist | 63 (29.7) | 524 (29.4) | 55 (18.8) | 348 (27.3) | 38 (15.5) | 49 (7.9) | 1077 (24.3) | 823 (17.7) |
| Total gonadotropin dose (IU) |
2700 [2025–3450] |
2200 [1575–3000] |
3000 [2325–3450] |
2700 [2250–3450] |
3075 [2700–4050] |
3075 [2480–3900] |
2700 [2000–3450] |
2025 [1455–2700] |
| Gonadotropin type: | ||||||||
| rFSH | 56 (26.4) | 755 (42.3) | 56 (19.1) | 351 (27.5) | 55 (22.5) | 101 (16.2) | 1374 (31.0) | 2451 (52.8) |
| rFSH+hMG | 134 (63.2) | 864 (48.4) | 160 (54.6) | 706 (55.4) | 156 (63.7) | 395 (63.4) | 2415 (54.5) | 1865 (40.2) |
| rFSH+rLH | 11 (5.2) | 92 (5.1) | 71 (24.2) | 179 (14.1) | 24 (9.8) | 110 (17.7) | 487 (11.0) | 259 (5.6) |
| hMG | 11 (5.2) | 74 (4.1) | 6 (2.0) | 39 (3.0) | 10 (4.0) | 17 (2.7) | 157 (3.5) | 65 (1.4) |
| Trigger type: | ||||||||
| hCG | 208 (98.1) | 1719 (96.3) | 262 (89.4) | 1213 (95.1) | 234 (95.5) | 577 (92.6) | 4213 (95.0) | 3712 (80.0) |
| GnRH agonist | 4 (1.9) | 66 (3.7) | 31 (10.6) | 62 (4.9) | 11 (4.5) | 46 (7.4) | 220 (5.0) | 928 (20.0) |
| Elective embryo freezing | 16 (7.5) | 180 (10.1) | 36 (12.3) | 208 (16.3) | 17 (6.9) | 69 (11.0) | 526 (11.9) | 1083 (23.3) |
Values are median and interquartile range or number and percentage. AFC, antral follicle count; AMH, anti-Müllerian hormone; rFSH, recombinant follicle-stimulating hormone; HMG, human menopausal gonadotropin; rLH, recombinant luteinizing hormone.
Group 1a: Younger (<35 years) unexpected poor responder (<4 oocytes retrieved); Group 1b: Younger (<35 years) unexpected suboptimal responder (4–9 oocytes retrieved); POSEIDON group 2a: Older (≥35 years) unexpected poor responder; Group 2b: Older unexpected suboptimal responder; Group 3: Younger expected poor responder; Group 4: Older expected poor responder; Group 5: Non-POSEIDON: normal responders (>9 oocytes retrieved) with an adequate AFC (≥5).
Based on data of 5750 patients.
Presence of both a male and a female factor.